-
July 11, 2012
A week before the deadline it has set for potential buyers to come from, Human Genome Sciences says regulators in the US are again reviewing raxibacumab, its previously-rejected anthrax treatment
Full story
-
July 04, 2012
As its battle for control of Human Genome Sciences looks to be coming to an end, GlaxoSmithKline has lined up 12 directors to replace the entire board at the US biotech, according to Reuters
Full story
-
July 02, 2012
The latest chapter in GlaxoSmithKline's hostile $2.60 billion takeover attempt to buy Human Genome Sciences has seen the UK drugs major once again extend its offer.
Full story
-
June 18, 2012
Human Genome Sciences has set a deadline of July 16 for offers to acquire the company but its efforts to get hostile bidder GlaxoSmithKline to join the process seem to have fallen on deaf ears
Full story
-
June 11, 2012
GlaxoSmithKline has extended its offer to acquire Human Genome Sciences without upping its $2.60 billion bid, after hardly any shares have been tendered
Full story
-
May 31, 2012
GlaxoSmithKline is planning to replace the entire board of takeover target Human Genome Sciences, according to a Reuters report, and candidates from across the sector have been sounded out
Full story
-
May 30, 2012
A Human Genome Sciences shareholder is suing the US biotech in a bid to stop the firm from using its 'poison pill' to foil GlaxoSmithKline's hostile $2.60 billion takeover bid
Full story
-
May 24, 2012
GlaxoSmithKline could walk away from its $2.60 billion bid to buy Human Genome Sciences if the latter's board does not drop a 'poison pill' adopted last week to thwart the UK drug giant's hostile approach
Full story
-
May 18, 2012
Human Genome Sciences has adopted a shareholder rights plan in the face of GlaxoSmithKline's hostile offer and has again dismissed the latter's $2.60 billion bid as inadequate
Full story
-
April 20, 2012
In confirming its unsolicited $2.60 billion bid for Human Genome Sciences, which has been rejected, GlaxoSmithKline says it still hopes to push through the deal "on a friendly basis"
Full story